Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.

Clinical Status Assessed by a 7-point Ordinal Clinical Status Scale

Clinical status assessed by a 7-point ordinal scale on Day 7 7-point ordinary scale: 1. Death 2. Hospitalised, on invasive mechanical ventilation or ECMO 3. Hospitalised, on non-invasive ventilation or high flow oxygen devices 4. Hospitalised, requiring low flow supplemental oxygen 5. Hospitalised, not requiring supplemental oxygen -requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalised, not requiring supplemental oxygen -no longer requires ongoing medical care 7. Not hospitalised A higher score indicates a better outcome

Time frame: Day 7

Clinical Status Assessed by a 7-point Ordinal Clinical Status Scale on Day 14

7-point ordinal scale: 1. Death 2. Hospitalised, on invasive mechanical ventilation or ECMO 3. Hospitalised, on non-invasive ventilation or high flow oxygen devices 4. Hospitalised, requiring low flow supplemental oxygen 5. Hospitalised, not requiring supplemental oxygen -requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalised, not requiring supplemental oxygen -no longer requires ongoing medical care 7. Not hospitalised A higher score indicates a better outcome

Time frame: Day 14

Clinical Severity on Day 7, Day 14 and Day 28 Based on National Early Warning Score 2 (NEWS2) Score

NEWS2 is a summary score of six physiological parameters (respiratory rate, oxygen saturation, systolic blood pressure, heart rate, consciousness, temperature, and supplemental oxygen dependency). The parameters are assessed to generate a severity score classified as low: aggregate score 0-4, low - medium/medium: score of 3 in any individual parameter/aggregate score 5-6,high: aggregate score 7 or more. A higher score indicates a greater clinical risk. Clinical status assessed by a 7-point ordinal scale.7-point ordinary scale: 1. Death 2. Hospitalised,on invasive mechanical ventilation or ECMO 3. Hospitalised,on non-invasive ventilation or high flow oxygen devices 4. Hospitalised,requiring low flow supplemental oxygen 5. Hospitalised,not requiring supplemental oxygen -requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalised,not requiring supplemental oxygen -no longer requires ongoing medical care 7. Not hospitalised A higher score indicates a better outcome.

Time frame: Day 7, 14, and 28

Clinical Status Assessed by a 7-point Ordinal Clinical Status Scale on Day 28

Clinical status assessed by a 7-point ordinal clinical status scale on Day 28 (or at last observation if discharged or died prior to this time point) in those still hospitalised after Day 14 7-point ordinary scale: 1. Death 2. Hospitalised, on invasive mechanical ventilation or ECMO 3. Hospitalised, on non-invasive ventilation or high flow oxygen devices 4. Hospitalised, requiring low flow supplemental oxygen 5. Hospitalised, not requiring supplemental oxygen -requiring ongoing medical care (COVID-19 related or otherwise) 6. Hospitalised, not requiring supplemental oxygen -no longer requires ongoing medical care 7. Not hospitalised

Time frame: Day 28

SpO2 > 94% on Room Air

Number of participants SpO2 \> 94% on room air by day 28

Time frame: Day 28

Duration of Oxygen Therapy

Median (IQR) duration on oxygen therapy by day 28.

Time frame: Day 28

ICU Admission

Intensive care unit admission over entire study period

Time frame: Day 28

Duration of ICU

Number of days spent in ICU

Time frame: through study completion, 28 days

Mechanical Ventilation/ECMO Use

Use of mechanical ventilation/ECMO (extracorporeal membrane oxygenation) over study period

Time frame: Day 28

Timing of Remdesivir Exposure

Median (IQR) time from first symptoms to use of remdesivir

Time frame: Day 28

Timing From Hospitalisation to Remdesivir Exposure

Median (IQR) time from hospitalisation to use of remdesivir

Time frame: Day 28

Duration of Remdesivir Use

Median (IQR) duration of use of remdesivir

Time frame: Day 28

Readmission With COVID-19 Complications

Re-admission with COVID-19 complications or recurrence within 28 days of discharge and outcome

Time frame: Day 28